Vasogen to Host Conference Call to Discuss Pivotal Phase III SIMPADICO Results

Toronto, Ontario - March 10, 2006

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting chronic inflammation underlying cardiovascular and neurological disease, today announced that it will host a conference call on Monday, March 13, at 8:30 a.m. ET, to discuss the results of the SIMPADICO trial of its Celacade™ technology in peripheral arterial disease (PAD).

As previously announced, Dr. Jeffrey Olin is expected to present the initial results of the SIMPADICO trial on Sunday, March 12, at 2:45 p.m. E.T., at a Late-Breaking Clinical Trial session of the 55th Annual Scientific Session of the American College of Cardiology being held in Atlanta, Georgia. Dr. Olin is Professor of Medicine at the Mount Sinai School of Medicine, Director of Vascular Medicine at The Zena and Michael A. Wiener Cardiovascular Institute in New York, and Principal Investigator and Chairman of the Steering Committee for the SIMPADICO trial.

A press release providing details of the trial results will be issued at the time of Dr. Olin’s presentation. Interested parties are invited to participate in the conference call on Monday, March 13, at 8:30 a.m. ET, by connecting 10 minutes prior to the start of the call to one of the following:

Audio Web Cast*	www.vasogen.com
Direct Dial	416-695-6622
Toll-free	1-800-769-8320

A re-broadcast of the conference call may be accessed by:

Audio Web Cast*	www.vasogen.com
Direct Dial	1-800-758-7977 Pin code: 6133

Windows Media Player required*

About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company is currently in the final stages of completing two pivotal phase III programs targeting large cardiovascular markets. The 2,400-patient phase III ACCLAIM trial is a 176-center international study designed to further investigate the use of Celacade technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure. The 550-patient phase III SIMPADICO trial, which was closed out early, is a 50-center North American study designed to further investigate the use of Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease. These phase III programs are designed to support regulatory approval in North America and commercialization in North America and Europe. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders. VP025, which has completed phase I clinical development, is the lead product candidate from this new class of drugs.

---